NextPoint Stock
NextPoint Therapeutics is a clinical-stage biotechnology company developing immuno-oncology therapies targeting the HHLA2 pathway. Its platform focuses on novel checkpoint inhibitors designed to overcome resistance to existing PD-1/PD-L1 therapies and enhance anti-tumor immune responses in solid tumors.
For more NextPoint stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Ivan Cheung Chief Executive Officer |
| Paul Conrad, PhD Chief Business Officer |
| Leena Gandhi, PhD Chief Medical Officer |
